This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Hepatic Impairment
and you are
between 18 and 75
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with moderate and severe hepatic impairment.

Provided treatments

  • Drug: dabrafenib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02873650. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 5 volunteers for the current phase.
Official trial title:
A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function